Posted on 4/12/18
Ambra Health Partners with MC Healthcare
Ambra Health, makers of the leading cloud-based, medical image management suite, today announced the company has signed a distribution agreement with MC Healthcare, one of Japan's . . .
Posted on 4/12/18
Deerfield Leads Investment of up to $50 Million in Sollis Therapeutics' Innovative Solution for Sciatica Pain
Deerfield Management and Sollis Therapeutics today announced a Deerfield-led investment of up to $50 million in Sollis Therapeutics. The investment will support the development of an . . .
Posted on 4/11/18
Westmed Medical Group Named One of the 2018 Best Workplaces in Health Care & Biopharma
"Westmed Medical Group is honored to announce that Fortune and Great Place to Work are again recognizing us as one of the 2018 Best Workplaces in . . .
Posted on 4/11/18
Northwell Among "Best Workplaces in Health Care"
Northwell Health has been named one of the best places to work in health care by Fortune and partner Great Place to Work. New York'slargest health . . .
Posted on 4/11/18
Konica Minolta Healthcare, HydroCision Announce Distribution Agreement for TenJet System
WAYNE, N.J., April 11, 2018 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., a leader in MSK ultrasound, announced today a distribution agreement with HydroCision, Inc., . . .
Posted on 4/10/18
Zelis Healthcare and WLT Software Announce Partnership for Integrated ePayment Solutions
BEDMINSTER, N.J. & CLEARWATER, Fla.--(BUSINESS WIRE)--Zelis® Healthcare today announced a newly formed business alliance with WLT Software® to include integration with MediClaims, its comprehensive benefit and . . .
Posted on 4/8/18
Tyme and JAF Announce Sarcoma Treatment Collaboration
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed . . .
Posted on 4/5/18
Intercept Pharmaceuticals Prices Upsized $250 Million Public Offering
NEW YORK, April 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat . . .
Posted on 4/5/18
New Jersey Jury Finds J&J's Iconic Baby Powder Tainted By Asbestos
Johnson & Johnson (NYSE:JNJ) and talc mining company Imerys (OTC:IMYSF) are ordered by a New Jersey state court to pay at least $37Mto a plaintiff who . . .
Posted on 4/5/18
Pfizer Has Big Plans in Treating Lung Cancer
Pfizer Inc. (NYSE:PFE) already markets the $600-million-per-year lung cancer drug Xalkori, and next year, it could have two more lung cancer drugs on the market. Recently, . . .
Posted on 4/5/18
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes'(NASDAQ:ALKS) hopes for a speedy review of its depression drug ALKS-5461 were dashed earlier this week when the Food and Drug Administration (FDA) issued it a . . .
Posted on 4/4/18
Intercept Pharmaceuticals Announces Proposed $120 Million Public Offering
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat . . .
Posted on 4/4/18
Global Autism Project Partners With Rethink
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- Global Autism Project is excited to announce their new partnership with leading technology and behavioral health experts, Rethink . . .
Posted on 4/4/18
MTBC Announces $10.5 Million Public Offering of Non-Convertible Preferred Stock
SOMERSET, N.J., April 04, 2018 (GLOBE NEWSWIRE) -- MTBC (NASDAQ: MTBC) (NASDAQ: MTBCP), a leading provider of proprietary, cloud-based healthcare IT solutions and services, today announced . . .
Posted on 4/4/18
How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
Last week, Pfizer (NYSE:PFE) released positive results from its ATTR-ACT phase 3 trial testing tafamidis for patients with a rare disease called transthyretin (TTR) amyloidosis cardiomyopathy, . . .
Posted on 4/3/18
Synergy Pharma: One Perplexing Biotech With Upside
Synergy Pharma (SGYP) reported Q4 numbers that deviated from guidance in a positive manner. The investment thesis in the stock is further enhanced that better transparency . . .
Posted on 4/3/18
Why Pfizer's Big Win Is Bad News for Alnylam and Ionis
Pfizer Inc. (NYSE:PFE) recently scored a clinical trial win with a rare-disease drug the Food and Drug Administration rejected about six years ago. The big U.S. . . .
Posted on 4/2/18
UBM Americas’ Pharmaceutical Executive Opens Nominations for 2018 Emerging Pharma Leaders
ISELIN, N.J., April 02, 2018 (GLOBE NEWSWIRE) -- UBM Life Sciences Group’s Pharmaceutical Executive today opened nominations for Emerging Pharma Leaders, an awards program that for . . .
Posted on 4/2/18
SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax (nelipepimut-S) Clinical Trial
SELLAS Life Sciences Group Inc., (Nasdaq: SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced . . .
Posted on 4/2/18
Is Celgene a Beaten-Up Biotech Stock to Buy?
Biotechs are exposed to a litany of risks including patent expiration, clinical-trial failures, and advances by competitors. That can make it one of the trickiest industries . . .
Posted on 4/2/18
Is Pfizer Inc. a Buy?
Suppose it's April 2015. Someone asks you, "Is Pfizer (NYSE:PFE) a good stock to buy?" At the time, the big pharma company's sales and earnings were . . .
Posted on 4/2/18
Better Buy: AbbVie Inc. vs. Johnson & Johnson
AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) battle each other in the marketplace every day. But they also are partners. That's not an unusual scenario in . . .
Posted on 3/30/18
Is Regeneron Pharmaceuticals, Inc. a Buy?
Many biotech stocks have performed quite well over the last 12 months. But not Regeneron Pharmaceuticals (NASDAQ:REGN). For much of 2017, Regeneron outperformed its peers. Things . . .
Posted on 3/29/18
Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market
Citius Pharmaceuticals Inc. (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into . . .
Posted on 3/29/18
Verizon: Ignore The FUD
Verizon (VZ) is generally considered to be one of the most reliable names in income-seeking portfolios. The telecom giant has consistently hiked its dividends for more . . .

